Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
192
Views
1
CrossRef citations to date
0
Altmetric
Commentaries

JAK polymorphisms: jack of all cytokines, masters GVHD?

Kushi Kushekhara Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA;b Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA;c Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA;d Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA
&
Sophie Paczesnya Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA;b Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA;c Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA;d Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence[email protected]
Pages 255-256 | Published online: 09 Aug 2016

References

  • Paczesny S, Hanauer D, Sun Y, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45:1–11.
  • Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol. 2015;194:4604–4612.
  • Paczesny S, Raiker N, Brooks S, et al. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98:275–292.
  • Dickinson AM, Norden J. Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome? Int J Immunogenet. 2015;42:229–238.
  • Carniti C, Gimondi S, Vendramin A, et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res. 2015;21:3740–3749.
  • Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–2068.
  • Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123:3832–3842.
  • Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PloS One. 2014;9:e109799.
  • Balassa K, Krahking T, Remenyi P, et al. Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2017;58:391–398.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
  • Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res. 2012;40:2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.